Keywords
TocilizumabMedicineRANKLOsteoprotegerinBone marrowBone resorptionImmunohistochemistryRheumatoid arthritisOsteoclastOsteopontinInternal medicineCD68PathologyReceptorActivator (genetics)
Affiliated Institutions
Related Publications
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
Anti-IL-6 therapy induced suppression of the inflammatory response affects rapidly the disrupted bone homeostasis in active RA. An additional, possibly specific, effect of IL-6 ...
IL-6 in Inflammation, Immunity, and Disease
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase respons...
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17
IL-6/sIL-6R directly induced RANKL expression in RA-FLS and it is essential for RANKL induction by TNF-alpha and IL-17. Moreover, RANKL induction by IL-6/sIL-6R is mediated by t...
Publication Info
- Year
- 2011
- Type
- article
- Volume
- 32
- Issue
- 9
- Pages
- 2669-2674
- Citations
- 17
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
17
OpenAlex
Cite This
Katsuaki Kanbe,
Atsushi Nakamura,
Yasuo Inoue
et al.
(2011).
Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis.
Rheumatology International
, 32
(9)
, 2669-2674.
https://doi.org/10.1007/s00296-011-2021-9
Identifiers
- DOI
- 10.1007/s00296-011-2021-9